# US 2021/0080468 A1 · Use of hexokinase-2 in detection of rare tumor cells in body fluid sample and kit

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0080468 A1
- Document ID: US20210080468A1
- Status: Published application
- Kind: A1
- Application number: 17/103,190
- Filed: 2020-11-24
- Published: 2021-03-18
- Earliest claimed: 2019-04-10
- Assignees: Suzhou Junhui Biotechnology Co., Ltd.
- Applicants: Suzhou Junhui Biotechnology Co., Ltd.
- Inventors: Liu Yang; Yingqi Hua; Zhengdong Cai
- Web page: https://patentgrep.com/patent/US20210080468A1

## CPC

- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/56966: {Animal cells}
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/5752: of the lungs
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 2333/91215: with a definite EC number (2.7.1.-)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present application relates to use of hexokinase-2 and a kit for detecting rare tumor cells in body fluid sample. The present application, based on a principle of abnormal tumor cell energy metabolism, conducts a vitro detection by using a glycolysis marker hexokinase-2 (HK2) as a marker, and assists localization and selection of the rare tumor cells by an addressable microporous array chip or a glass sheet, so as to implement a detection on rare tumor cells having high glycolysis activity in a cancer patient's body fluid sample. The detection method of present application allows to detect rare tumor cells having high glycolysis activity in the human body fluid sample, especially detect circulating tumor cells of an interstitial origin tumor and the circulating tumor cells having epithelial-interstitial transformation in epithelial origin tumors, thereby covering the shortage of traditional detection against the circulating tumor cells based on an epithelial marker, and providing a technical basis for better application of cancer liquid biopsy in clinic.

## Claims

### Claim 1

A method for detecting rare tumor cells in a human body fluid sample, comprising: conducting a staining treatment on cells from the human body fluid sample with a fluorescein labeled hexokinase-2 (HK2) antibody substance; conducting a fluorescence detection on the cells after the staining treatment for identifying HK2 positive cells based on a fluorescence signal of HK2; and identifying cells with high HK2 levels as rare tumor cells.

### Claim 1

A method for detecting rare tumor cells in a human body fluid sample, comprising:
conducting a staining treatment on cells from the human body fluid sample with a fluorescein labeled hexokinase-2 (HK2) antibody substance; conducting a fluorescence detection on the cells after the staining treatment for identifying HK2 positive cells based on a fluorescence signal of HK2; and identifying cells with high HK2 levels as rare tumor cells.

### Claim 2 (depends on 1)

The method according to claim 1, wherein a threshold of high HK2 level is defined by a HK2 fluorescence intensity that is higher than a mean HK2 fluorescence value plus five times of standard deviation of all leucocytes in the human body fluid sample.

### Claim 2 (depends on 1)

The method according to claim 1, wherein a threshold of high HK2 level is defined by a HK2 fluorescence intensity that is higher than a mean HK2 fluorescence value plus five times of standard deviation of all leucocytes in the human body fluid sample.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising: conducting a staining treatment on the cells from the human body fluid sample with a fluorescein labeled antibody targeting leukocyte marker; conducting a staining treatment on the cells from the human body fluid sample with a cell nucleus stain; and identifying cells with high HK2 levels and negative in leukocyte marker staining and positive in cell nucleus staining as rare tumor cells.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising: conducting a staining treatment on the cells from the human body fluid sample with a fluorescein labeled antibody targeting leukocyte marker; conducting a staining treatment on the cells from the human body fluid sample with a cell nucleus stain; and identifying cells with high HK2 levels and negative in leukocyte marker staining and positive in cell nucleus staining as rare tumor cells.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the fluorescein labeled HK2 antibody substance is a fluorescein labeled HK2 antibody, or a combination of a HK2 antibody with a fluorescein labeled secondary antibody targeting HK2 primary antibody.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the fluorescein labeled HK2 antibody substance is a fluorescein labeled HK2 antibody, or a combination of a HK2 antibody with a fluorescein labeled secondary antibody targeting HK2 primary antibody.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the antibody targeting leukocyte marker is an antibody against cell membrane surface protein CD45, and the cell nucleus stain is a fluorescent dye targeting cell nucleus, wherein mean HK2 fluorescence value plus five times of standard deviation of the CD45 positive cells is defined as a threshold for determining high HK2 level.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the antibody targeting leukocyte marker is an antibody against cell membrane surface protein CD45, and the cell nucleus stain is a fluorescent dye targeting cell nucleus, wherein mean HK2 fluorescence value plus five times of standard deviation of the CD45 positive cells is defined as a threshold for determining high HK2 level.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1 to 5, wherein the human body fluid sample refers to blood, pleural effusion, cerebrospinal fluid or urine sample, wherein after conducting a selective enrichment treatment to the human body fluid sample, a cell suspension is prepared and a single cell monolayer of the cell suspension in an addressable microwell array chip or a glass slide is prepared for subsequent staining treatment, wherein the selective enrichment treatment comprises decreasing numbers of erythrocyte and/or leukocyte in the human body fluid sample.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the human body fluid sample refers to blood, pleural effusion, cerebrospinal fluid or urine sample, wherein after conducting a selective enrichment treatment to the human body fluid sample, a cell suspension is prepared and a single cell monolayer of the cell suspension in an addressable microwell array chip or a glass slide is prepared for subsequent staining treatment, wherein the selective enrichment treatment comprises decreasing numbers of erythrocyte and/or leukocyte in the human body fluid sample.

### Claim 7

A kit for detecting rare tumor cells, comprising: a fluorescein labeled antibody targeting HK2, a fluorescein labeled antibody targeting leukocyte marker, and a nucleus stain.

### Claim 7

A kit for detecting rare tumor cells, comprising: a fluorescein labeled antibody targeting HK2, a fluorescein labeled antibody targeting leukocyte marker, and a nucleus stain.

### Claim 8

Use of an anti-HK2 antibody substance in:
a) detection of rare tumor cells for a non-diagnostic purpose; or
b) preparation of a rare tumor cells detection kit; or
c) serving as a tumor cell marker for detection of rare tumor cells.

### Claim 8

Use of an anti-HK2 antibody substance in:
a) detection of rare tumor cells for a non-diagnostic purpose; or
b) preparation of a rare tumor cells detection kit; or
c) serving as a tumor cell marker for detection of rare tumor cells.

### Claim 9 (depends on 8)

The use according to claim 8, wherein cells with high HK2 levels and negative in leukocyte marker and positive in nucleus staining in a human body fluid sample are identified as the rare tumor cells, and epithelial cell marker negative rare tumor cells in the human body fluid sample are identified as tumor cells having epithelial-mesenchymal transformation or tumor cells of mesenchymal origin, the cell with high HK2 level referring to a cell in which the fluorescence intensity is higher than a predetermined threshold after HK2 fluorescent staining treatment.

### Claim 9 (depends on 8)

The use according to claim 8, wherein cells with high HK2 levels and negative in leukocyte marker and positive in nucleus staining in a human body fluid sample are identified as the rare tumor cells, and epithelial cell marker negative rare tumor cells in the human body fluid sample are identified as tumor cells having epithelial-mesenchymal transformation or tumor cells of mesenchymal origin, the cell with high HK2 level referring to a cell in which the fluorescence intensity is higher than a predetermined threshold after HK2 fluorescent staining treatment.

### Claim 10

Combined use of a HK2 antibody substance and an epithelial cell marker antibody substance in preparation of a detection kit for identifying CTC characteristics, wherein the HK2 antibody substance is a fluorescein labeled antibody targeting HK2, or a combination of a HK2 antibody with a fluorescein labeled secondary antibody targeting HK2 primary antibody , wherein the epithelial cell marker antibody substance is a fluorescein labeled CK antibody, wherein the CTC characteristics refers to characteristics for distinguishing CTC cells as epithelial origin tumor cells, tumor cells having epithelial-interstitial transformation, or tumor cells of interstitial origin, wherein the kit comprises a fluorescein labeled antibody targeting the leukocyte marker, a cell nucleus stain, and an instruction recording: confirming epithelial cell marker positive cells in the CTC cells as epithelial origin tumor cells; and confirming epithelial cell marker negative cells as tumor cells having epithelial-interstitial transformation, or as tumor cells of interstitial origin.

### Claim 10

Combined use of a HK2 antibody substance and an epithelial cell marker antibody substance in preparation of a detection kit for identifying CTC characteristics, wherein the HK2 antibody substance is a fluorescein labeled antibody targeting HK2, or a combination of a HK2 antibody with a fluorescein labeled secondary antibody targeting HK2 primary antibody , wherein the epithelial cell marker antibody substance is a fluorescein labeled CK antibody, wherein the CTC characteristics refers to characteristics for distinguishing CTC cells as epithelial origin tumor cells, tumor cells having epithelial-interstitial transformation, or tumor cells of interstitial origin, wherein the kit comprises a fluorescein labeled antibody targeting the leukocyte marker, a cell nucleus stain, and an instruction recording: confirming epithelial cell marker positive cells in the CTC cells as epithelial origin tumor cells; and confirming epithelial cell marker negative cells as tumor cells having epithelial-interstitial transformation, or as tumor cells of interstitial origin.
